Related Experiment Video

Updated: May 14, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Histone deacetylase inhibitors: novel agents in cancer treatment

Erica Glass1, Pamela Hallquist Viale

  • 1St. Agnes Cancer Institute, Baltimore, MD, USA. ericaglass@hotmail.com

Clinical Journal of Oncology Nursing
|February 2, 2013
PubMed

Insights

Histone deacetylase inhibitors (HDAC-Is) show promise as anticancer agents. Oncology nurses need to understand HDAC-Is for patient care, especially in treating cutaneous T-cell lymphoma.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Histone deacetylase inhibitors (HDAC-Is) exhibit anticancer properties in preclinical and clinical studies.
  • Current FDA-approved HDAC-Is include vorinostat and romidepsin, primarily for cutaneous T-cell lymphoma.
  • Expanding clinical trials suggest broader applications for HDAC-Is in various cancers.

Purpose of the Study:

  • To review the mechanism of action of HDAC-Is.
  • To discuss currently approved HDAC-Is and their indications.
  • To outline nursing management strategies for patients receiving HDAC-Is, focusing on cutaneous T-cell lymphoma.

Main Methods:

  • Literature review of HDAC-Is mechanism of action.
  • Summary of FDA-approved HDAC-Is and their clinical uses.
  • Discussion of nursing considerations for HDAC-Is therapy.

Main Results:

  • HDAC-Is function by inhibiting histone deacetylase enzymes, leading to altered gene expression and anticancer effects.
  • Vorinostat and romidepsin are approved for cutaneous T-cell lymphoma, with romidepsin also indicated for peripheral T-cell lymphoma.
  • Clinical trials are exploring HDAC-Is in other malignancies, indicating potential for wider therapeutic use.

Conclusions:

  • HDAC-Is represent a significant class of anticancer agents with established and emerging roles.
  • Oncology nurses require comprehensive knowledge of HDAC-Is for effective patient management.
  • This review provides essential information on HDAC-Is, approved therapies, and nursing care for cutaneous T-cell lymphoma patients.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...